For research use only
| Cat No. | ABC-TC0110 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Product Code | CaLu-1; CALU-1; Calu.1; CALU 1; Calu 1; CALU1; Calu1 |
The Calu-1 cell line is a human lung carcinoma model used for cancer research, signaling pathway studies, and drug screening assays in vitro.
Calu-1 is a human non-small cell lung carcinoma (NSCLC) line derived in 1971 from a pleural metastasis in a 47-year-old Caucasian male with grade III epidermoid carcinoma of the lung. These cells grow adherently with an epithelial, polygonal morphology and feature pronounced microvilli, abundant rough endoplasmic reticulum, lysosomes, and lipid inclusions. They exhibit a moderate growth rate, which supports reproducible in vitro proliferation studies. Genetically, Calu-1 expresses wild-type STK11 (also known as LKB1) and EGFR, harbors a KRAS p.G12C oncogenic mutation, and lacks functional p53 and FHIT tumor suppressors due to homozygous deletions. Functional studies reveal Calu-1 has active voltage-gated sodium channels linked to enhanced migration and invasiveness. Together, these characteristics make Calu-1 a robust NSCLC model, especially for studying KRAS-driven tumor behaviors and epithelial features. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | CaLu-1; CALU-1; Calu.1; CALU 1; Calu 1; CALU1; Calu1 |
| Species | Human |
| Cat.No | ABC-TC0110 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
Calu-1 serves as a valuable in vitro and in vivo model for investigating KRAS p.G12C-driven lung cancer mechanisms, particularly in squamous cell carcinoma contexts. Its intrinsic resistance to EGFR-targeted therapies like erlotinib enables studies into drug resistance pathways. Invasion assays, including 3D co-culture with fibroblasts, demonstrate a high epithelial-to-mesenchymal transition (EMT) signature and collective-to-single cell invasive transition—making Calu-1 particularly suited for metastasis and tumor-stroma interaction studies. The functional sodium channel activity also supports research into bioelectric signaling in cancer progression and potential ion channel-targeted therapeutic strategies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
